Mycenax Biotech Inc. (TWSE: 4726) signed a memorandum of understanding (MoU) with CHO Pharma Inc. (TWSE: 6586) today. With CHO Pharma's leading global proprietary technology platform, CHOptimaxTM, that enhances antibody efficacy, Mycenax will become the world's first contract development and manufacturing organization (CDMO) partner of CHO Pharma to provide commercialized manufacturing services. This partnership will further accelerate the development of next-generation antibody production and its application.
CHOptimaxTM is a revolutionary glycoengineered technology for homogeneous antibodies independently developed by CHO Pharma. It uses the most exclusive proprietary key enzymes to produce antibodies with the best glycan structure rapidly. Our technological breakthrough has simplified the original process and significantly reduced production cost, reaching a new milestone of commercial application. CHO-V10, a second-generation COVID-19 vaccine, has been successfully developed using the CHOptimaxTM platform to neutralize various SARS-CoV-2 mutant strains, including the South African strain.
Chairman of Mycenax, Mr. Jung-Chin Lin, expressed Mycenax's devotion to becoming a world-class CDMO company and its expertise in cell therapy and various technological developments. Mycenax will become one of the few CDMO companies with multiple protein and antibody production lines and experience in innovative technology, promoting the industry's competitiveness. Mycenax is exceptionally pleased to work with CHO Pharma. Synthesizing CHO Pharma's glycoengineered technology for homogeneous antibodies with Mycenax' cell line development and GMP production effectively achieves mass production specifications and expands the application of multiple-generation antibodies.
Chairman of CHO Pharma, Chao-Long Chen, M.D., Ph.D., indicated that CHO Pharma is committed to establishing itself as a leading glycol-biotechnical pharmaceutical company through its innovative technology platform. Through this collaboration with Mycenax, its world-leading technology platform, CHOptimaxTM, will reach a new milestone in the industry.
Mycenax has decades of extensive experience in developing and manufacturing biological drugs. This collaboration will meet requirements of commercial specifications production, significantly reduce production costs, and provide CHO Pharma's glycoengineered technology with valuable services, expanding generations of antibody applications. This collaboration will benefit CHO Pharma's products and allow both companies to seek potential partners through the CHOptimaxTM platform to further consolidate Mycenax' CDMO business, providing benefits for both companies.
About Mycenax Biotech Inc.
Mycenax Biotech Inc., established in 2001, is a biopharmaceutical company leading in CMC development and GMP manufacturing in Taiwan. Its expertise includes cell line development, process development, formulation, analytical methods, GMP manufacturing, and aseptic filling. With manufacturing facilities based in Taiwan, Mycenax integrates the upstream and downstream process development to provide a complete product and manufacturing service for global customers.
Mycenax Biotech Inc. (TWSE: 4726) signed a memorandum of understanding (MoU) with CHO Pharma Inc. (TWSE: 6586) today. With CHO Pharma's leading global proprietary technology platform, CHOptimaxTM, that enhances antibody efficacy, Mycenax will become the world's first contract development and manufacturing organization (CDMO) partner of CHO Pharma to provide commercialized manufacturing services. This partnership will further accelerate the development of next-generation antibody production and its application.
CHOptimaxTM is a revolutionary glycoengineered technology for homogeneous antibodies independently developed by CHO Pharma. It uses the most exclusive proprietary key enzymes to produce antibodies with the best glycan structure rapidly. Our technological breakthrough has simplified the original process and significantly reduced production cost, reaching a new milestone of commercial application. CHO-V10, a second-generation COVID-19 vaccine, has been successfully developed using the CHOptimaxTM platform to neutralize various SARS-CoV-2 mutant strains, including the South African strain.
Chairman of Mycenax, Mr. Jung-Chin Lin, expressed Mycenax's devotion to becoming a world-class CDMO company and its expertise in cell therapy and various technological developments. Mycenax will become one of the few CDMO companies with multiple protein and antibody production lines and experience in innovative technology, promoting the industry's competitiveness. Mycenax is exceptionally pleased to work with CHO Pharma. Synthesizing CHO Pharma's glycoengineered technology for homogeneous antibodies with Mycenax' cell line development and GMP production effectively achieves mass production specifications and expands the application of multiple-generation antibodies.
Chairman of CHO Pharma, Chao-Long Chen, M.D., Ph.D., indicated that CHO Pharma is committed to establishing itself as a leading glycol-biotechnical pharmaceutical company through its innovative technology platform. Through this collaboration with Mycenax, its world-leading technology platform, CHOptimaxTM, will reach a new milestone in the industry.
Mycenax has decades of extensive experience in developing and manufacturing biological drugs. This collaboration will meet requirements of commercial specifications production, significantly reduce production costs, and provide CHO Pharma's glycoengineered technology with valuable services, expanding generations of antibody applications. This collaboration will benefit CHO Pharma's products and allow both companies to seek potential partners through the CHOptimaxTM platform to further consolidate Mycenax' CDMO business, providing benefits for both companies.
About Mycenax Biotech Inc.
Mycenax Biotech Inc., established in 2001, is a biopharmaceutical company leading in CMC development and GMP manufacturing in Taiwan. Its expertise includes cell line development, process development, formulation, analytical methods, GMP manufacturing, and aseptic filling. With manufacturing facilities based in Taiwan, Mycenax integrates the upstream and downstream process development to provide a complete product and manufacturing service for global customers.